PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the first patient into the WIND-PSC study. PSC is a rare.
Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -
- Reduction in Patient-Reported Pruritus was.
WASHINGTON — Seladelpar use led to “rapid, marked and sustained improvement” in markers of cholestasis and liver injury among patients with primary biliary cholangitis, according to interim results of the ongoing, phase 3 ASSURE study.
“The study was initiated because there is currently a major unmet need for patients with primary biliary cholangitis (PBC) and insufficient
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.